Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALOMA-2: Subcutaneous Amivantamab in Multiple Regimens for Advanced or Metastatic EGFR-mutated NSCLC
NCT05498428Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, open-label trial of amivantamab in non-small cell lung cancer (NSCLC) (8 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Objective Response Rate Based on Investigator Assessment at 1.5 years, Number of Participants with Adverse Events at 1.5 years and 3 more. Started Nov 2022; status: recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05498428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498428.